Global Targeted PSMA Radionuclide Drug Conjugates Supply, Demand and Key Producers, 2026-2032
The global Targeted PSMA Radionuclide Drug Conjugates market size is expected to reach $ 3466 million by 2032, rising at a market growth of 7.5% CAGR during the forecast period (2026-2032).
Targeted PSMA Radionuclide Drug Conjugates are precision radiotherapeutics designed to selectively deliver therapeutic radioisotopes to tumor tissue by targeting prostate-specific membrane antigen, or PSMA. These products are typically composed of a PSMA-targeting small molecule or ligand, a chelator, and a therapeutic radionuclide. Among current commercialized and clinical-stage products, 177Lu-labeled agents are the most mature, while alpha-emitting candidates such as 225Ac-based products are still largely in clinical development or early-stage application. This category is primarily used for the treatment of PSMA-positive advanced prostate cancer, especially metastatic castration-resistant prostate cancer, or mCRPC. Upstream segments mainly include targeting ligands and precursors, chelators, radioisotope production and purification, sterile radiopharmaceutical filling, and specialized cold-chain logistics, while downstream customers mainly consist of hospitals with nuclear medicine capabilities, cancer centers, specialty treatment networks, and radiopharmaceutical distribution systems. On a commercial-market basis, the global market in 2025 remained centered on Novartis? Pluvicto, and the industry as a whole continued to show the characteristics of limited marketed products, an active clinical pipeline, and simultaneous technical and supply-chain barriers. Because these products combine the economics of innovative oncology drugs with the operational barriers of radiopharmaceutical manufacturing, including isotope supply, dedicated facilities, quality-release requirements, and specialized distribution, gross margin is generally higher than that of conventional small-molecule drugs and standard injectables. In 2025, the gross margin of commercialized targeted PSMA radionuclide drug conjugates is estimated to be in the range of 55%-70%.
At present, the targeted PSMA radionuclide drug conjugate industry is in a stage driven by a limited number of commercialized products while accelerating into broader treatment settings. As the leading marketed products gradually move toward earlier lines of therapy, the sector is shifting from late-line clinical validation to a phase characterized by indication expansion and platform-based commercialization. This indicates that both the clinical value and commercial feasibility of the category are continuing to strengthen. Overall, market attention, capital investment, and pipeline activity are all increasing, and the industry is evolving from isolated product breakthroughs toward sustained competition centered on platform capability and indication expansion.
From the perspective of technology and product evolution, the 177Lu route is expected to remain the mainstream direction in the medium term because of its relatively mature clinical pathway, more established industrial infrastructure, and stronger commercialization foundation. At the same time, however, the industry is moving from competition around individual products to competition around platform capability. Future development is likely to focus not only on new ligand structures, combination regimens, and earlier treatment settings, but also on accelerated deployment of alpha-emitter approaches such as 225Ac in pursuit of stronger biological effects and differentiated therapeutic value. As leading companies continue to broaden their radioligand therapy portfolios, targeted PSMA drugs are likely to evolve from a single advanced prostate cancer therapy into a core component of broader radiopharmaceutical oncology platforms.
From an industrialization perspective, supply chain and manufacturing systems will be the key variables determining how quickly the industry can scale. Compared with conventional oncology drugs, targeted PSMA radionuclide drug conjugates place much higher demands on isotope supply, specialized manufacturing facilities, quality release, time-sensitive distribution, and hospital nuclear medicine capabilities. In the future, leading companies are expected to continue strengthening delivery resilience by expanding radiopharmaceutical production sites, building regional manufacturing networks, and increasing treatment-center coverage. As a result, competition will no longer be limited to the drug itself, but will increasingly become competition in integrated capabilities spanning product, manufacturing, logistics, and hospital access. In other words, companies that establish stable isotope access and strong treatment networks earlier will be better positioned in the commercialization phase.
Nevertheless, the industry still faces several constraints. Stable isotope supply, the construction cycle of dedicated capacity, and the availability of specialized treatment centers remain practical bottlenecks to market expansion. In addition, patient treatment pathways usually rely on PSMA imaging selection and supporting nuclear medicine infrastructure, while reimbursement systems, hospital access, and treatment standards differ significantly across countries and regions, making global market expansion uneven. As the category moves into earlier treatment settings and addresses a broader patient population, requirements for safety management, treatment standardization, and long-term follow-up data will also continue to rise. Overall, targeted PSMA radionuclide drug conjugates offer clear long-term growth potential, but future expansion is more likely to be gradual and system-driven, supported jointly by clinical evidence, supply assurance, and healthcare infrastructure development, rather than by rapid short-term scaling.
This report studies the global Targeted PSMA Radionuclide Drug Conjugates demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Targeted PSMA Radionuclide Drug Conjugates, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Targeted PSMA Radionuclide Drug Conjugates that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Targeted PSMA Radionuclide Drug Conjugates total market, 2021-2032, (USD Million)
Global Targeted PSMA Radionuclide Drug Conjugates total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Targeted PSMA Radionuclide Drug Conjugates total market, key domestic companies, and share, (USD Million)
Global Targeted PSMA Radionuclide Drug Conjugates revenue by player, revenue and market share 2021-2026, (USD Million)
Global Targeted PSMA Radionuclide Drug Conjugates total market by Type, CAGR, 2021-2032, (USD Million)
Global Targeted PSMA Radionuclide Drug Conjugates total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Targeted PSMA Radionuclide Drug Conjugates market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Curium, Telix Pharmaceuticals, Lantheus, Fusion Pharmaceuticals, Blue Earth Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Targeted PSMA Radionuclide Drug Conjugates market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Targeted PSMA Radionuclide Drug Conjugates Market, By Region:
1. How big is the global Targeted PSMA Radionuclide Drug Conjugates market?
2. What is the demand of the global Targeted PSMA Radionuclide Drug Conjugates market?
3. What is the year over year growth of the global Targeted PSMA Radionuclide Drug Conjugates market?
4. What is the total value of the global Targeted PSMA Radionuclide Drug Conjugates market?
5. Who are the Major Players in the global Targeted PSMA Radionuclide Drug Conjugates market?
6. What are the growth factors driving the market demand?
Targeted PSMA Radionuclide Drug Conjugates are precision radiotherapeutics designed to selectively deliver therapeutic radioisotopes to tumor tissue by targeting prostate-specific membrane antigen, or PSMA. These products are typically composed of a PSMA-targeting small molecule or ligand, a chelator, and a therapeutic radionuclide. Among current commercialized and clinical-stage products, 177Lu-labeled agents are the most mature, while alpha-emitting candidates such as 225Ac-based products are still largely in clinical development or early-stage application. This category is primarily used for the treatment of PSMA-positive advanced prostate cancer, especially metastatic castration-resistant prostate cancer, or mCRPC. Upstream segments mainly include targeting ligands and precursors, chelators, radioisotope production and purification, sterile radiopharmaceutical filling, and specialized cold-chain logistics, while downstream customers mainly consist of hospitals with nuclear medicine capabilities, cancer centers, specialty treatment networks, and radiopharmaceutical distribution systems. On a commercial-market basis, the global market in 2025 remained centered on Novartis? Pluvicto, and the industry as a whole continued to show the characteristics of limited marketed products, an active clinical pipeline, and simultaneous technical and supply-chain barriers. Because these products combine the economics of innovative oncology drugs with the operational barriers of radiopharmaceutical manufacturing, including isotope supply, dedicated facilities, quality-release requirements, and specialized distribution, gross margin is generally higher than that of conventional small-molecule drugs and standard injectables. In 2025, the gross margin of commercialized targeted PSMA radionuclide drug conjugates is estimated to be in the range of 55%-70%.
At present, the targeted PSMA radionuclide drug conjugate industry is in a stage driven by a limited number of commercialized products while accelerating into broader treatment settings. As the leading marketed products gradually move toward earlier lines of therapy, the sector is shifting from late-line clinical validation to a phase characterized by indication expansion and platform-based commercialization. This indicates that both the clinical value and commercial feasibility of the category are continuing to strengthen. Overall, market attention, capital investment, and pipeline activity are all increasing, and the industry is evolving from isolated product breakthroughs toward sustained competition centered on platform capability and indication expansion.
From the perspective of technology and product evolution, the 177Lu route is expected to remain the mainstream direction in the medium term because of its relatively mature clinical pathway, more established industrial infrastructure, and stronger commercialization foundation. At the same time, however, the industry is moving from competition around individual products to competition around platform capability. Future development is likely to focus not only on new ligand structures, combination regimens, and earlier treatment settings, but also on accelerated deployment of alpha-emitter approaches such as 225Ac in pursuit of stronger biological effects and differentiated therapeutic value. As leading companies continue to broaden their radioligand therapy portfolios, targeted PSMA drugs are likely to evolve from a single advanced prostate cancer therapy into a core component of broader radiopharmaceutical oncology platforms.
From an industrialization perspective, supply chain and manufacturing systems will be the key variables determining how quickly the industry can scale. Compared with conventional oncology drugs, targeted PSMA radionuclide drug conjugates place much higher demands on isotope supply, specialized manufacturing facilities, quality release, time-sensitive distribution, and hospital nuclear medicine capabilities. In the future, leading companies are expected to continue strengthening delivery resilience by expanding radiopharmaceutical production sites, building regional manufacturing networks, and increasing treatment-center coverage. As a result, competition will no longer be limited to the drug itself, but will increasingly become competition in integrated capabilities spanning product, manufacturing, logistics, and hospital access. In other words, companies that establish stable isotope access and strong treatment networks earlier will be better positioned in the commercialization phase.
Nevertheless, the industry still faces several constraints. Stable isotope supply, the construction cycle of dedicated capacity, and the availability of specialized treatment centers remain practical bottlenecks to market expansion. In addition, patient treatment pathways usually rely on PSMA imaging selection and supporting nuclear medicine infrastructure, while reimbursement systems, hospital access, and treatment standards differ significantly across countries and regions, making global market expansion uneven. As the category moves into earlier treatment settings and addresses a broader patient population, requirements for safety management, treatment standardization, and long-term follow-up data will also continue to rise. Overall, targeted PSMA radionuclide drug conjugates offer clear long-term growth potential, but future expansion is more likely to be gradual and system-driven, supported jointly by clinical evidence, supply assurance, and healthcare infrastructure development, rather than by rapid short-term scaling.
This report studies the global Targeted PSMA Radionuclide Drug Conjugates demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Targeted PSMA Radionuclide Drug Conjugates, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Targeted PSMA Radionuclide Drug Conjugates that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Targeted PSMA Radionuclide Drug Conjugates total market, 2021-2032, (USD Million)
Global Targeted PSMA Radionuclide Drug Conjugates total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Targeted PSMA Radionuclide Drug Conjugates total market, key domestic companies, and share, (USD Million)
Global Targeted PSMA Radionuclide Drug Conjugates revenue by player, revenue and market share 2021-2026, (USD Million)
Global Targeted PSMA Radionuclide Drug Conjugates total market by Type, CAGR, 2021-2032, (USD Million)
Global Targeted PSMA Radionuclide Drug Conjugates total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Targeted PSMA Radionuclide Drug Conjugates market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Curium, Telix Pharmaceuticals, Lantheus, Fusion Pharmaceuticals, Blue Earth Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Targeted PSMA Radionuclide Drug Conjugates market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Targeted PSMA Radionuclide Drug Conjugates Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Monotherapy Products
- Combination Therapy Products
- Beta-emitting
- Alpha-emitting
- Other
- Small-molecule
- Antibody-based
- Other
- Hospital
- Clinic
- Others
- Novartis
- Curium
- Telix Pharmaceuticals
- Lantheus
- Fusion Pharmaceuticals
- Blue Earth Therapeutics
1. How big is the global Targeted PSMA Radionuclide Drug Conjugates market?
2. What is the demand of the global Targeted PSMA Radionuclide Drug Conjugates market?
3. What is the year over year growth of the global Targeted PSMA Radionuclide Drug Conjugates market?
4. What is the total value of the global Targeted PSMA Radionuclide Drug Conjugates market?
5. Who are the Major Players in the global Targeted PSMA Radionuclide Drug Conjugates market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Targeted PSMA Radionuclide Drug Conjugates Introduction
1.2 World Targeted PSMA Radionuclide Drug Conjugates Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Targeted PSMA Radionuclide Drug Conjugates Total Market by Region (by Headquarter Location)
1.3.1 World Targeted PSMA Radionuclide Drug Conjugates Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032)
1.3.3 China Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032)
1.3.4 Europe Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032)
1.3.5 Japan Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032)
1.3.6 South Korea Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032)
1.3.7 ASEAN Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032)
1.3.8 India Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Targeted PSMA Radionuclide Drug Conjugates Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032)
2.2 World Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Region
2.2.1 World Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Region (2021-2026)
2.2.2 World Targeted PSMA Radionuclide Drug Conjugates Consumption Value Forecast by Region (2027-2032)
2.3 United States Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032)
2.4 China Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032)
2.5 Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032)
2.6 Japan Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032)
2.7 South Korea Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032)
2.8 ASEAN Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032)
2.9 India Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032)
3 WORLD TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES COMPANIES COMPETITIVE ANALYSIS
3.1 World Targeted PSMA Radionuclide Drug Conjugates Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Targeted PSMA Radionuclide Drug Conjugates Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Targeted PSMA Radionuclide Drug Conjugates in 2025
3.2.3 Global Concentration Ratios (CR8) for Targeted PSMA Radionuclide Drug Conjugates in 2025
3.3 Targeted PSMA Radionuclide Drug Conjugates Company Evaluation Quadrant
3.4 Targeted PSMA Radionuclide Drug Conjugates Market: Overall Company Footprint Analysis
3.4.1 Targeted PSMA Radionuclide Drug Conjugates Market: Region Footprint
3.4.2 Targeted PSMA Radionuclide Drug Conjugates Market: Company Product Type Footprint
3.4.3 Targeted PSMA Radionuclide Drug Conjugates Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Targeted PSMA Radionuclide Drug Conjugates Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Targeted PSMA Radionuclide Drug Conjugates Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Targeted PSMA Radionuclide Drug Conjugates Consumption Value Comparison
4.2.1 United States VS China: Targeted PSMA Radionuclide Drug Conjugates Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Targeted PSMA Radionuclide Drug Conjugates Companies and Market Share, 2021-2026
4.3.1 United States Based Targeted PSMA Radionuclide Drug Conjugates Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue, (2021-2026)
4.4 China Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue and Market Share, 2021-2026
4.4.1 China Based Targeted PSMA Radionuclide Drug Conjugates Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue, (2021-2026)
4.5 Rest of World Based Targeted PSMA Radionuclide Drug Conjugates Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Targeted PSMA Radionuclide Drug Conjugates Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Targeted PSMA Radionuclide Drug Conjugates Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Monotherapy Products
5.2.2 Combination Therapy Products
5.3 Market Segment by Type
5.3.1 World Targeted PSMA Radionuclide Drug Conjugates Market Size by Type (2021-2026)
5.3.2 World Targeted PSMA Radionuclide Drug Conjugates Market Size by Type (2027-2032)
5.3.3 World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY RADIONUCLIDE TYPE
6.1 World Targeted PSMA Radionuclide Drug Conjugates Market Size Overview by Radionuclide Type: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Radionuclide Type
6.2.1 Beta-emitting
6.2.2 Alpha-emitting
6.2.3 Other
6.3 Market Segment by Radionuclide Type
6.3.1 World Targeted PSMA Radionuclide Drug Conjugates Market Size by Radionuclide Type (2021-2026)
6.3.2 World Targeted PSMA Radionuclide Drug Conjugates Market Size by Radionuclide Type (2027-2032)
6.3.3 World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Radionuclide Type (2027-2032)
7 MARKET ANALYSIS BY TARGETING VECTOR TYPE
7.1 World Targeted PSMA Radionuclide Drug Conjugates Market Size Overview by Targeting Vector Type: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Targeting Vector Type
7.2.1 Small-molecule
7.2.2 Antibody-based
7.2.3 Other
7.3 Market Segment by Targeting Vector Type
7.3.1 World Targeted PSMA Radionuclide Drug Conjugates Market Size by Targeting Vector Type (2021-2026)
7.3.2 World Targeted PSMA Radionuclide Drug Conjugates Market Size by Targeting Vector Type (2027-2032)
7.3.3 World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Targeting Vector Type (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Targeted PSMA Radionuclide Drug Conjugates Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospital
8.2.2 Clinic
8.2.3 Others
8.3 Market Segment by Application
8.3.1 World Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2021-2026)
8.3.2 World Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2027-2032)
8.3.3 World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Novartis
9.1.1 Novartis Details
9.1.2 Novartis Major Business
9.1.3 Novartis Targeted PSMA Radionuclide Drug Conjugates Product and Services
9.1.4 Novartis Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Novartis Recent Developments/Updates
9.1.6 Novartis Competitive Strengths & Weaknesses
9.2 Curium
9.2.1 Curium Details
9.2.2 Curium Major Business
9.2.3 Curium Targeted PSMA Radionuclide Drug Conjugates Product and Services
9.2.4 Curium Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Curium Recent Developments/Updates
9.2.6 Curium Competitive Strengths & Weaknesses
9.3 Telix Pharmaceuticals
9.3.1 Telix Pharmaceuticals Details
9.3.2 Telix Pharmaceuticals Major Business
9.3.3 Telix Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Product and Services
9.3.4 Telix Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Telix Pharmaceuticals Recent Developments/Updates
9.3.6 Telix Pharmaceuticals Competitive Strengths & Weaknesses
9.4 Lantheus
9.4.1 Lantheus Details
9.4.2 Lantheus Major Business
9.4.3 Lantheus Targeted PSMA Radionuclide Drug Conjugates Product and Services
9.4.4 Lantheus Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Lantheus Recent Developments/Updates
9.4.6 Lantheus Competitive Strengths & Weaknesses
9.5 Fusion Pharmaceuticals
9.5.1 Fusion Pharmaceuticals Details
9.5.2 Fusion Pharmaceuticals Major Business
9.5.3 Fusion Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Product and Services
9.5.4 Fusion Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Fusion Pharmaceuticals Recent Developments/Updates
9.5.6 Fusion Pharmaceuticals Competitive Strengths & Weaknesses
9.6 Blue Earth Therapeutics
9.6.1 Blue Earth Therapeutics Details
9.6.2 Blue Earth Therapeutics Major Business
9.6.3 Blue Earth Therapeutics Targeted PSMA Radionuclide Drug Conjugates Product and Services
9.6.4 Blue Earth Therapeutics Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Blue Earth Therapeutics Recent Developments/Updates
9.6.6 Blue Earth Therapeutics Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Targeted PSMA Radionuclide Drug Conjugates Industry Chain
10.2 Targeted PSMA Radionuclide Drug Conjugates Upstream Analysis
10.3 Targeted PSMA Radionuclide Drug Conjugates Midstream Analysis
10.4 Targeted PSMA Radionuclide Drug Conjugates Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Targeted PSMA Radionuclide Drug Conjugates Introduction
1.2 World Targeted PSMA Radionuclide Drug Conjugates Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Targeted PSMA Radionuclide Drug Conjugates Total Market by Region (by Headquarter Location)
1.3.1 World Targeted PSMA Radionuclide Drug Conjugates Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032)
1.3.3 China Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032)
1.3.4 Europe Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032)
1.3.5 Japan Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032)
1.3.6 South Korea Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032)
1.3.7 ASEAN Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032)
1.3.8 India Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Targeted PSMA Radionuclide Drug Conjugates Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032)
2.2 World Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Region
2.2.1 World Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Region (2021-2026)
2.2.2 World Targeted PSMA Radionuclide Drug Conjugates Consumption Value Forecast by Region (2027-2032)
2.3 United States Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032)
2.4 China Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032)
2.5 Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032)
2.6 Japan Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032)
2.7 South Korea Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032)
2.8 ASEAN Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032)
2.9 India Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032)
3 WORLD TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES COMPANIES COMPETITIVE ANALYSIS
3.1 World Targeted PSMA Radionuclide Drug Conjugates Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Targeted PSMA Radionuclide Drug Conjugates Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Targeted PSMA Radionuclide Drug Conjugates in 2025
3.2.3 Global Concentration Ratios (CR8) for Targeted PSMA Radionuclide Drug Conjugates in 2025
3.3 Targeted PSMA Radionuclide Drug Conjugates Company Evaluation Quadrant
3.4 Targeted PSMA Radionuclide Drug Conjugates Market: Overall Company Footprint Analysis
3.4.1 Targeted PSMA Radionuclide Drug Conjugates Market: Region Footprint
3.4.2 Targeted PSMA Radionuclide Drug Conjugates Market: Company Product Type Footprint
3.4.3 Targeted PSMA Radionuclide Drug Conjugates Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Targeted PSMA Radionuclide Drug Conjugates Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Targeted PSMA Radionuclide Drug Conjugates Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Targeted PSMA Radionuclide Drug Conjugates Consumption Value Comparison
4.2.1 United States VS China: Targeted PSMA Radionuclide Drug Conjugates Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Targeted PSMA Radionuclide Drug Conjugates Companies and Market Share, 2021-2026
4.3.1 United States Based Targeted PSMA Radionuclide Drug Conjugates Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue, (2021-2026)
4.4 China Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue and Market Share, 2021-2026
4.4.1 China Based Targeted PSMA Radionuclide Drug Conjugates Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue, (2021-2026)
4.5 Rest of World Based Targeted PSMA Radionuclide Drug Conjugates Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Targeted PSMA Radionuclide Drug Conjugates Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Targeted PSMA Radionuclide Drug Conjugates Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Monotherapy Products
5.2.2 Combination Therapy Products
5.3 Market Segment by Type
5.3.1 World Targeted PSMA Radionuclide Drug Conjugates Market Size by Type (2021-2026)
5.3.2 World Targeted PSMA Radionuclide Drug Conjugates Market Size by Type (2027-2032)
5.3.3 World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY RADIONUCLIDE TYPE
6.1 World Targeted PSMA Radionuclide Drug Conjugates Market Size Overview by Radionuclide Type: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Radionuclide Type
6.2.1 Beta-emitting
6.2.2 Alpha-emitting
6.2.3 Other
6.3 Market Segment by Radionuclide Type
6.3.1 World Targeted PSMA Radionuclide Drug Conjugates Market Size by Radionuclide Type (2021-2026)
6.3.2 World Targeted PSMA Radionuclide Drug Conjugates Market Size by Radionuclide Type (2027-2032)
6.3.3 World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Radionuclide Type (2027-2032)
7 MARKET ANALYSIS BY TARGETING VECTOR TYPE
7.1 World Targeted PSMA Radionuclide Drug Conjugates Market Size Overview by Targeting Vector Type: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Targeting Vector Type
7.2.1 Small-molecule
7.2.2 Antibody-based
7.2.3 Other
7.3 Market Segment by Targeting Vector Type
7.3.1 World Targeted PSMA Radionuclide Drug Conjugates Market Size by Targeting Vector Type (2021-2026)
7.3.2 World Targeted PSMA Radionuclide Drug Conjugates Market Size by Targeting Vector Type (2027-2032)
7.3.3 World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Targeting Vector Type (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Targeted PSMA Radionuclide Drug Conjugates Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospital
8.2.2 Clinic
8.2.3 Others
8.3 Market Segment by Application
8.3.1 World Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2021-2026)
8.3.2 World Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2027-2032)
8.3.3 World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Novartis
9.1.1 Novartis Details
9.1.2 Novartis Major Business
9.1.3 Novartis Targeted PSMA Radionuclide Drug Conjugates Product and Services
9.1.4 Novartis Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Novartis Recent Developments/Updates
9.1.6 Novartis Competitive Strengths & Weaknesses
9.2 Curium
9.2.1 Curium Details
9.2.2 Curium Major Business
9.2.3 Curium Targeted PSMA Radionuclide Drug Conjugates Product and Services
9.2.4 Curium Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Curium Recent Developments/Updates
9.2.6 Curium Competitive Strengths & Weaknesses
9.3 Telix Pharmaceuticals
9.3.1 Telix Pharmaceuticals Details
9.3.2 Telix Pharmaceuticals Major Business
9.3.3 Telix Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Product and Services
9.3.4 Telix Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Telix Pharmaceuticals Recent Developments/Updates
9.3.6 Telix Pharmaceuticals Competitive Strengths & Weaknesses
9.4 Lantheus
9.4.1 Lantheus Details
9.4.2 Lantheus Major Business
9.4.3 Lantheus Targeted PSMA Radionuclide Drug Conjugates Product and Services
9.4.4 Lantheus Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Lantheus Recent Developments/Updates
9.4.6 Lantheus Competitive Strengths & Weaknesses
9.5 Fusion Pharmaceuticals
9.5.1 Fusion Pharmaceuticals Details
9.5.2 Fusion Pharmaceuticals Major Business
9.5.3 Fusion Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Product and Services
9.5.4 Fusion Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Fusion Pharmaceuticals Recent Developments/Updates
9.5.6 Fusion Pharmaceuticals Competitive Strengths & Weaknesses
9.6 Blue Earth Therapeutics
9.6.1 Blue Earth Therapeutics Details
9.6.2 Blue Earth Therapeutics Major Business
9.6.3 Blue Earth Therapeutics Targeted PSMA Radionuclide Drug Conjugates Product and Services
9.6.4 Blue Earth Therapeutics Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Blue Earth Therapeutics Recent Developments/Updates
9.6.6 Blue Earth Therapeutics Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Targeted PSMA Radionuclide Drug Conjugates Industry Chain
10.2 Targeted PSMA Radionuclide Drug Conjugates Upstream Analysis
10.3 Targeted PSMA Radionuclide Drug Conjugates Midstream Analysis
10.4 Targeted PSMA Radionuclide Drug Conjugates Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Targeted PSMA Radionuclide Drug Conjugates Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Targeted PSMA Radionuclide Drug Conjugates Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Targeted PSMA Radionuclide Drug Conjugates Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Targeted PSMA Radionuclide Drug Conjugates Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Targeted PSMA Radionuclide Drug Conjugates Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Targeted PSMA Radionuclide Drug Conjugates Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Targeted PSMA Radionuclide Drug Conjugates Players in 2025
Table 12. World Targeted PSMA Radionuclide Drug Conjugates Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Targeted PSMA Radionuclide Drug Conjugates Company Evaluation Quadrant
Table 14. Head Office of Key Targeted PSMA Radionuclide Drug Conjugates Players
Table 15. Targeted PSMA Radionuclide Drug Conjugates Market: Company Product Type Footprint
Table 16. Targeted PSMA Radionuclide Drug Conjugates Market: Company Product Application Footprint
Table 17. Targeted PSMA Radionuclide Drug Conjugates Mergers & Acquisitions Activity
Table 18. United States VS China Targeted PSMA Radionuclide Drug Conjugates Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Targeted PSMA Radionuclide Drug Conjugates Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Targeted PSMA Radionuclide Drug Conjugates Companies, Headquarters (States, Country)
Table 21. United States Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share (2021-2026)
Table 23. China Based Targeted PSMA Radionuclide Drug Conjugates Companies, Headquarters (Province, Country)
Table 24. China Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share (2021-2026)
Table 26. Rest of World Based Targeted PSMA Radionuclide Drug Conjugates Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share (2021-2026)
Table 29. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Targeted PSMA Radionuclide Drug Conjugates Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Type (2027-2032) & (USD Million)
Table 32. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Radionuclide Type, (USD Million), 2021 & 2025 & 2032
Table 33. World Targeted PSMA Radionuclide Drug Conjugates Market Size Value by Radionuclide Type (2021-2026) & (USD Million)
Table 34. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Radionuclide Type (2027-2032) & (USD Million)
Table 35. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Targeting Vector Type, (USD Million), 2021 & 2025 & 2032
Table 36. World Targeted PSMA Radionuclide Drug Conjugates Market Size Value by Targeting Vector Type (2021-2026) & (USD Million)
Table 37. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Targeting Vector Type (2027-2032) & (USD Million)
Table 38. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2021-2026) & (USD Million)
Table 40. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2027-2032) & (USD Million)
Table 41. Novartis Basic Information, Manufacturing Base and Competitors
Table 42. Novartis Major Business
Table 43. Novartis Targeted PSMA Radionuclide Drug Conjugates Product and Services
Table 44. Novartis Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Novartis Recent Developments/Updates
Table 46. Novartis Competitive Strengths & Weaknesses
Table 47. Curium Basic Information, Manufacturing Base and Competitors
Table 48. Curium Major Business
Table 49. Curium Targeted PSMA Radionuclide Drug Conjugates Product and Services
Table 50. Curium Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Curium Recent Developments/Updates
Table 52. Curium Competitive Strengths & Weaknesses
Table 53. Telix Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 54. Telix Pharmaceuticals Major Business
Table 55. Telix Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Product and Services
Table 56. Telix Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Telix Pharmaceuticals Recent Developments/Updates
Table 58. Telix Pharmaceuticals Competitive Strengths & Weaknesses
Table 59. Lantheus Basic Information, Manufacturing Base and Competitors
Table 60. Lantheus Major Business
Table 61. Lantheus Targeted PSMA Radionuclide Drug Conjugates Product and Services
Table 62. Lantheus Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Lantheus Recent Developments/Updates
Table 64. Lantheus Competitive Strengths & Weaknesses
Table 65. Fusion Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 66. Fusion Pharmaceuticals Major Business
Table 67. Fusion Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Product and Services
Table 68. Fusion Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Fusion Pharmaceuticals Recent Developments/Updates
Table 70. Fusion Pharmaceuticals Competitive Strengths & Weaknesses
Table 71. Blue Earth Therapeutics Basic Information, Manufacturing Base and Competitors
Table 72. Blue Earth Therapeutics Major Business
Table 73. Blue Earth Therapeutics Targeted PSMA Radionuclide Drug Conjugates Product and Services
Table 74. Blue Earth Therapeutics Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Blue Earth Therapeutics Recent Developments/Updates
Table 76. Blue Earth Therapeutics Competitive Strengths & Weaknesses
Table 77. Global Key Players of Targeted PSMA Radionuclide Drug Conjugates Upstream (Raw Materials)
Table 78. Global Targeted PSMA Radionuclide Drug Conjugates Typical Customers
Table 1. World Targeted PSMA Radionuclide Drug Conjugates Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Targeted PSMA Radionuclide Drug Conjugates Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Targeted PSMA Radionuclide Drug Conjugates Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Targeted PSMA Radionuclide Drug Conjugates Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Targeted PSMA Radionuclide Drug Conjugates Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Targeted PSMA Radionuclide Drug Conjugates Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Targeted PSMA Radionuclide Drug Conjugates Players in 2025
Table 12. World Targeted PSMA Radionuclide Drug Conjugates Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Targeted PSMA Radionuclide Drug Conjugates Company Evaluation Quadrant
Table 14. Head Office of Key Targeted PSMA Radionuclide Drug Conjugates Players
Table 15. Targeted PSMA Radionuclide Drug Conjugates Market: Company Product Type Footprint
Table 16. Targeted PSMA Radionuclide Drug Conjugates Market: Company Product Application Footprint
Table 17. Targeted PSMA Radionuclide Drug Conjugates Mergers & Acquisitions Activity
Table 18. United States VS China Targeted PSMA Radionuclide Drug Conjugates Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Targeted PSMA Radionuclide Drug Conjugates Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Targeted PSMA Radionuclide Drug Conjugates Companies, Headquarters (States, Country)
Table 21. United States Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share (2021-2026)
Table 23. China Based Targeted PSMA Radionuclide Drug Conjugates Companies, Headquarters (Province, Country)
Table 24. China Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share (2021-2026)
Table 26. Rest of World Based Targeted PSMA Radionuclide Drug Conjugates Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share (2021-2026)
Table 29. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Targeted PSMA Radionuclide Drug Conjugates Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Type (2027-2032) & (USD Million)
Table 32. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Radionuclide Type, (USD Million), 2021 & 2025 & 2032
Table 33. World Targeted PSMA Radionuclide Drug Conjugates Market Size Value by Radionuclide Type (2021-2026) & (USD Million)
Table 34. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Radionuclide Type (2027-2032) & (USD Million)
Table 35. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Targeting Vector Type, (USD Million), 2021 & 2025 & 2032
Table 36. World Targeted PSMA Radionuclide Drug Conjugates Market Size Value by Targeting Vector Type (2021-2026) & (USD Million)
Table 37. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Targeting Vector Type (2027-2032) & (USD Million)
Table 38. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2021-2026) & (USD Million)
Table 40. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2027-2032) & (USD Million)
Table 41. Novartis Basic Information, Manufacturing Base and Competitors
Table 42. Novartis Major Business
Table 43. Novartis Targeted PSMA Radionuclide Drug Conjugates Product and Services
Table 44. Novartis Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Novartis Recent Developments/Updates
Table 46. Novartis Competitive Strengths & Weaknesses
Table 47. Curium Basic Information, Manufacturing Base and Competitors
Table 48. Curium Major Business
Table 49. Curium Targeted PSMA Radionuclide Drug Conjugates Product and Services
Table 50. Curium Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Curium Recent Developments/Updates
Table 52. Curium Competitive Strengths & Weaknesses
Table 53. Telix Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 54. Telix Pharmaceuticals Major Business
Table 55. Telix Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Product and Services
Table 56. Telix Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Telix Pharmaceuticals Recent Developments/Updates
Table 58. Telix Pharmaceuticals Competitive Strengths & Weaknesses
Table 59. Lantheus Basic Information, Manufacturing Base and Competitors
Table 60. Lantheus Major Business
Table 61. Lantheus Targeted PSMA Radionuclide Drug Conjugates Product and Services
Table 62. Lantheus Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Lantheus Recent Developments/Updates
Table 64. Lantheus Competitive Strengths & Weaknesses
Table 65. Fusion Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 66. Fusion Pharmaceuticals Major Business
Table 67. Fusion Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Product and Services
Table 68. Fusion Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Fusion Pharmaceuticals Recent Developments/Updates
Table 70. Fusion Pharmaceuticals Competitive Strengths & Weaknesses
Table 71. Blue Earth Therapeutics Basic Information, Manufacturing Base and Competitors
Table 72. Blue Earth Therapeutics Major Business
Table 73. Blue Earth Therapeutics Targeted PSMA Radionuclide Drug Conjugates Product and Services
Table 74. Blue Earth Therapeutics Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Blue Earth Therapeutics Recent Developments/Updates
Table 76. Blue Earth Therapeutics Competitive Strengths & Weaknesses
Table 77. Global Key Players of Targeted PSMA Radionuclide Drug Conjugates Upstream (Raw Materials)
Table 78. Global Targeted PSMA Radionuclide Drug Conjugates Typical Customers
LIST OF FIGURES
Figure 1. Targeted PSMA Radionuclide Drug Conjugates Picture
Figure 2. World Targeted PSMA Radionuclide Drug Conjugates Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Targeted PSMA Radionuclide Drug Conjugates Total Revenue (2021-2032) & (USD Million)
Figure 4. World Targeted PSMA Radionuclide Drug Conjugates Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032) & (USD Million)
Figure 13. Targeted PSMA Radionuclide Drug Conjugates Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 16. World Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 18. China Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 23. India Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Targeted PSMA Radionuclide Drug Conjugates by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Targeted PSMA Radionuclide Drug Conjugates Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Targeted PSMA Radionuclide Drug Conjugates Markets in 2025
Figure 27. United States VS China: Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Type in 2025
Figure 31. Monotherapy Products
Figure 32. Combination Therapy Products
Figure 33. World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Type (2021-2032)
Figure 34. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Radionuclide Type, (USD Million), 2021 & 2025 & 2032
Figure 35. World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Radionuclide Type in 2025
Figure 36. Beta-emitting
Figure 37. Alpha-emitting
Figure 38. Other
Figure 39. World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Radionuclide Type (2021-2032)
Figure 40. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Targeting Vector Type, (USD Million), 2021 & 2025 & 2032
Figure 41. World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Targeting Vector Type in 2025
Figure 42. Small-molecule
Figure 43. Antibody-based
Figure 44. Other
Figure 45. World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Targeting Vector Type (2021-2032)
Figure 46. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 47. World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Application in 2025
Figure 48. Hospital
Figure 49. Clinic
Figure 50. Others
Figure 51. World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2032)
Figure 52. Targeted PSMA Radionuclide Drug Conjugates Industrial Chain
Figure 53. Methodology
Figure 54. Research Process and Data Source
Figure 1. Targeted PSMA Radionuclide Drug Conjugates Picture
Figure 2. World Targeted PSMA Radionuclide Drug Conjugates Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Targeted PSMA Radionuclide Drug Conjugates Total Revenue (2021-2032) & (USD Million)
Figure 4. World Targeted PSMA Radionuclide Drug Conjugates Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2032) & (USD Million)
Figure 13. Targeted PSMA Radionuclide Drug Conjugates Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 16. World Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 18. China Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 23. India Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Targeted PSMA Radionuclide Drug Conjugates by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Targeted PSMA Radionuclide Drug Conjugates Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Targeted PSMA Radionuclide Drug Conjugates Markets in 2025
Figure 27. United States VS China: Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Type in 2025
Figure 31. Monotherapy Products
Figure 32. Combination Therapy Products
Figure 33. World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Type (2021-2032)
Figure 34. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Radionuclide Type, (USD Million), 2021 & 2025 & 2032
Figure 35. World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Radionuclide Type in 2025
Figure 36. Beta-emitting
Figure 37. Alpha-emitting
Figure 38. Other
Figure 39. World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Radionuclide Type (2021-2032)
Figure 40. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Targeting Vector Type, (USD Million), 2021 & 2025 & 2032
Figure 41. World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Targeting Vector Type in 2025
Figure 42. Small-molecule
Figure 43. Antibody-based
Figure 44. Other
Figure 45. World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Targeting Vector Type (2021-2032)
Figure 46. World Targeted PSMA Radionuclide Drug Conjugates Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 47. World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Application in 2025
Figure 48. Hospital
Figure 49. Clinic
Figure 50. Others
Figure 51. World Targeted PSMA Radionuclide Drug Conjugates Market Size Market Share by Application (2021-2032)
Figure 52. Targeted PSMA Radionuclide Drug Conjugates Industrial Chain
Figure 53. Methodology
Figure 54. Research Process and Data Source
